Antibodies

08 Nov 2019 Affimed Announces FDA Clearance of IND to Commence First-in-Human Phase 1/2a Study of AFM24 for the Treatment of EGFR-Expressing Cancers
08 Nov 2019 EMD Serono and Pfizer Provide Update on Phase III JAVELIN Gastric 100 Trial
08 Nov 2019 Teva and Celltrion Announce the Availability of TRUXIMA® (rituximab-abbs) Injection, the First Biosimilar to Rituxan® (rituximab) in the United States
08 Nov 2019 Alpine Immune Sciences Presents New Preclinical Data at The Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting
08 Nov 2019 AVEO Oncology and Biodesix Announce Initiation of the CyFi-2 Study, a Phase 2 Randomized Study of Ficlatuzumab in Combination with High-Dose Cytarabine vs. High-Dose Cytarabine Alone in Patients with Relapsed and Refractory AML
08 Nov 2019 AvantGen Enters a Strategic Collaboration Agreement to Develop Novel Anti-Cancer Therapeutic With Its NK Cell Engager Technology
08 Nov 2019 F-star Presents New Data on OX40/CD137 Tetravalent Bispecific Antibody at the SITC 2019 Annual Meeting
06 Nov 2019 Coherus Acquires Commercial Rights for Leading Lucentis Biosimilar in the United States
06 Nov 2019 Samsung Bioepis Enters into Commercialization Agreement for Next-Generation Biosimilar Candidates
06 Nov 2019 Compugen Presents Initial Clinical Data from Ongoing Phase 1 Trial of COM701 in Patients with Advanced Solid Tumors at SITC 2019
06 Nov 2019 Compugen Presents Preclinical Data for COM902 Anti-TIGIT Program at SITC 2019
05 Nov 2019 SciRhom Initiates First-In-Class Antibody Development Program to Treat Major Autoimmune Diseases
04 Nov 2019 Compugen Announces FDA Clearance of IND Application for COM902
04 Nov 2019 Harbour BioMed Announces Initiation of First-in-human Study of Next-generation Anti-CTLA-4 Antibody for Treatment of Solid Tumors
01 Nov 2019 Pinteon Therapeutics Launches Phase 1 Trial of Novel Tau Antibody that Targets a Potent Driver of Neurodegenerative Disease
01 Nov 2019 Novartis Cosentyx® shows encouraging results versus Humira®* from first-of-its-kind head-to-head trial in psoriatic arthritis
31 Oct 2019 Daiichi Sankyo Initiates Clinical Trial with its 4th DXd Antibody Drug Conjugate, DS-7300, in Collaboration with Sarah Cannon Research Institute
30 Oct 2019 CytomX Therapeutics Announces Initiation of Phase 2 Clinical Trial Evaluating the Anti-PD-L1 Probody CX-072 in Combination with YERVOY® in Patients with Relapsed or Refractory Melanoma
30 Oct 2019 FDA Accepts Genentech’s Biologics License Application for Satralizumab for Neuromyelitis Optica Spectrum Disorder
29 Oct 2019 Harpoon Therapeutics Presents Preclinical Data for HPN328, a DLL3-targeting T Cell Engager, at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
29 Oct 2019 Sutro Biopharma Presents Encouraging Preliminary Clinical Data in Ongoing Phase I Study for STRO-002 Antibody-Drug Conjugate in Patients with Advanced Ovarian Cancer
29 Oct 2019 Intravenous Benlysta is the first biologic treatment to be approved for children with lupus in Europe
29 Oct 2019 Dupixent® (dupilumab) now approved in European Union for severe chronic rhinosinusitis with nasal polyposis
29 Oct 2019 European Commission Approves BAVENCIO® (avelumab) Plus Axitinib Combination for First-Line Treatment of Patients With Advanced Renal Cell Carcinoma
29 Oct 2019 MOR106 Clinical Development in Atopic Dermatitis Stopped for Futility

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top